High-Yielding Synthesis of the Anti-Influenza Neuramidase Inhibitor (-)-Oseltamivir by Three "One-Pot" Operations
High-Yielding Synthesis of the Anti-Influenza Neuramidase Inhibitor (-)-Oseltamivir by Three "One-Pot" Operations
复制标题
DOI：
10.1002/anie.200804883
复制
发表时间：
2009-01-01
影响因子：
16.6
通讯作者：
Hayashi, Yujiro
中科院分区：
文献类型：
--
作者：
Ishikawa, Hayato;Suzuki, Takaki;Hayashi, Yujiro
A great deal of attention has been paid both in the scientific literature and the general media to the high potential risk of a worldwide spread of avian H5N1 influenza virus, the death rate of which is over 50%.[1] Indeed, should this virus acquire the ability to become capable of spreading easily and directly from human to human it could very possibly cause a disastrous pandemic.(À)-Oseltamivir phosphate (Tamiflu), a neuraminidase inhibitor used in the treatment of both type A and type B human influenza,[2] is one of the most promising therapeutics, and many nations have plans to stock a significant amount of this compound in case of a possible influenza outbreak. Moreover, the recent emergence of Tamiflu-resistant virus strains has prompted the chemical community to develop medicines effective against the mutated virus.[3] To meet these demands, intensive efforts have been devoted to the development of efficient preparations of this life-saving drug [1, 2, 4] and of its derivatives. For our synthesis of Tamiflu, we set the following objectives, because meeting these requirements would allow a large amount to be prepared in a short time and at low cost: 1) The number of synthetic reactions should be not more than ten, and the number of separate operations should be as few as possible. 2) The overall yield should be over 50%. 3) Only inexpensive reagents should be employed. Preparing a molecule of this complexity, possessing three contiguous chiral centers, in no more than ten synthetic reactions in over 50% overall yield is a very challenging goal. Even if each individual reaction of a sequence proceeds in 90% yield—an excellent yield in organic synthesis—the overall yield falls to 35% after ten reactions (0.910= 0.35). The best yield yet achieved for the total synthesis of Tamiflu is approximately 35%.[4b, d] Moreover, in order to supply Tamiflu to developing countries where influenza might spread, production costs should be kept low. This requires that only inexpensive reagents be used. Although several syntheses of Tamiflu have been reported, previous methods do not meet all these requirements, and developing a method which does so remains a great challenge for the chemical community. One-pot operations are effective for carrying out several transformations and forming several bonds in a single pot, while at the same time cutting out several purification steps, minimizing chemical waste generation, and saving time. To simplify the synthesis we investigated the preparation of Tamiflu by a small number of one-pot operations. Our strategy was to construct a key, fully functionalized ethyl cyclohexenecarboxylate intermediate in a single-pot operation as the first step; after this, the remainder of the synthesis consists simply of functional group manipulations, also carried out in one-pot operations. The first key reaction relied on organocatalysis, a relatively new, rapidly developing technology in synthetic organic chemistry.[5] Diphenylprolinol silyl ether 4,[6] which was developed independently by our group [7] and Jørgensen s group,[8] acts as an effective organocatalyst, promoting many kinds of asymmetric reactions with excellent enantioselectivities. We have already reported the highly enantioselective Michael reactions of aldehydes and nitroalkenes catalyzed by ether 4,[7a] which was also elegantly employed by Enders and co-workers in a domino reaction with α, β-enals to prepare tetrasubstituted cyclohexenecarbaldehydes.[9] We applied our reaction to the present synthesis using the three simple starting materials alkoxyaldehyde 2, nitroalkene 3, and diethyl vinylphosphonate derivative 5; subsequent treatment with p-toluenethiol afforded the …
